Related Experiment Videos
TGF-beta is not the principal immunosuppressive component in coagulation factor concentrates
H J Pearson1, D Stirling, C A Ludlam
1Department of Haematology, The Royal Infirmary of Edinburgh, Edinburgh.
Insights
Coagulation factor concentrates exhibit immunosuppressive effects, but TGF-beta is not the sole cause. Other contaminants likely contribute to this activity, indicating complex immunomodulatory mechanisms.
Area of Science:
- Immunology
- Hematology
Background:
- Coagulation factor concentrates are known to modulate immune responses in vitro.
- Their potential immunomodulatory effects warrant further investigation.
Purpose of the Study:
- To assess the immunomodulatory activity of various coagulation factor concentrates.
- To investigate the role of TGF-beta in the observed immunosuppressive effects.
Main Methods:
- Measured inhibition of PHA-stimulated lymphocyte proliferation and IL-2 secretion.
- Quantified TGF-beta levels and compared with immunosuppressive activity.
- Utilized TGF-beta-specific bioassays and lymphocyte proliferation assays.
Main Results:
- A broad correlation was observed between TGF-beta levels and immunosuppressive activity, but with discrepancies.
- Coagulation factors showed significantly lower potency than pure TGF-beta in immunosuppression assays.
- Anti-TGF-beta antibodies only partially reversed the immunosuppressive effects of coagulation factors.
Conclusions:
- TGF-beta accounts for only a minor part of the immunosuppressive activity of coagulation factor concentrates.
- Other immunomodulatory contaminants likely contribute to the observed immunosuppression.
- The immunosuppressive activity is not attributable to a single substance.
Abstract:
Coagulation factor concentrates are known to inhibit a variety of immune reactions when assessed in vitro. This study assessed the immunomodulatory activity of a wide range of coagulation factor concentrates by measuring their inhibition of PHA-stimulated lymphocyte proliferation and reduction in IL-2 secretion. The hypothesis that TGF-beta is responsible for most of these effects was tested by measuring biologically active TGF-beta and immunoreactive TGF-beta1 in the concentrates and comparing the levels recorded with immunosuppressive activity. In addition, the coagulation factors were compared directly with a standard preparation of TGF-beta in a TGF-beta-specific bioassay and in lymphocyte proliferation assays. Although there was a broad correlation between levels of total or active TGF-beta and immunosuppressive activity across all of the coagulation factors tested, individual data sets showed clear discrepancies. Implying that TGF-beta probably serves as a surrogate marker for other immunomodulatory contaminants and that neither TGF-beta nor any other single substance could account for all of the immunosuppressive activity observed. Furthermore, there was a difference of more than 100-fold in the relative potencies of coagulation factors and pure TGF-beta, when compared in immunosuppression assays, indicating that the different assays did not measure the same substance. Whereas anti-TGF-beta antibody almost completely blocked the activity of coagulation factor concentrates (TGF-beta-specific bioassay) and abrogated the effect of authentic TGF-beta (immunosuppression assays) at high concentrations it achieved <50% reversal of the immunosuppressive effects of coagulation factors in immunosuppression assays. These findings indicated that TGF-beta accounted for only a minor proportion of the immunosuppressive activity in most coagulation factor concentrates.